New pill aims to ease chronic pain without opioids
NCT ID NCT06810245
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested whether an experimental pill called PIPE-791 is safe and can lower pain in adults with long-term osteoarthritis knee pain or chronic low back pain. 43 participants stopped their usual pain meds, then took either the study drug or a placebo daily for 4 weeks, then switched for another 4 weeks. The main goal was to check for side effects and see if pain levels improved.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
43 people
The number who actually took part.
- Started
-
Feb 2025
- Finished
-
Jan 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Key Inclusion Criteria * Male or female 18 to 70 years of age, inclusive, at the first Screening visit. * Only one of the following chronic pain diagnoses at least 6 months prior to Screening: * Osteoarthritis of the knee OR low back pain (with or without painful lumbosacral radiculopathy) * Plain radiographs of the knee or lumbar spine consistent with diagnosis within 9 months prior to or during Screening. * History of related daily pain for at least 6 months prior to Screening. * Have a body mass index \<40 (inclusive) at Screening. * Willing to maintain a consistent regimen of any ongoing (stable format and frequency for the duration of study participation) non-pharmacologic pain-relieving therapies. * Willing to discontinue medications taken for chronic pain conditions and usage of transcutaneous electrical nerve stimulation for the duration of the study. * Male or female subjects with reproductive potential agree to comply with a highly effective contraceptive method as per protocol through 90 days after last study drug administration. * Subjects taking systemic hormone-replacement therapy must be on a stable dose and regimen for at least 1 month prior to Screening. * General good medical health with no clinically significant or relevant abnormalities except those attributed to the underlying chronic pain condition, including medical history, physical exam, vital signs, ECG, and laboratory evaluations (hematology, chemistry, and urinalysis) as assessed by the Investigator. * Ability to use an eDiary to record daily pain scores. Key Exclusion Criteria * History of refractory chronic pain after multiple failed treatments as determined by the Investigator (e.g., no response to all of the following: surgery and/or nerve blocks, a regimen of at least two non-opioid pharmacotherapies, and physical rehabilitation, and weak opioids). * Concurrent diagnosis of fibromyalgia or evidence of chronic widespread pain, or other pain that may interfere with the assessment of CLBP or COAP. * Demonstrated noncompliance recording daily Numerical Rating Scale (NRS) scores during Screening. * Have had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest, e.g., an ablation procedure. * Received capsaicin treatment (e.g., Qutenza) within the past 3 months prior to screening. * Have surgery planned during the study for any reason, related or not, to the disease state under evaluation. * Are non-ambulatory (use of assistive devices is allowed). * History of Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, arthritis associated with inflammatory bowel disease, sarcoidosis, or amyloidosis. * Diagnosed with OA during childhood or adolescence, including post-traumatic OA or OA due to genetic (e.g., hip dysplasia) or congenital (e.g., metabolic disorders) conditions. * History of or clinical signs or symptoms of active joint infection, crystal disease of the knee, or a history of arthritis due to crystals (e.g., gout, pseudo gout). * History of prior lumbar or thoracic spine surgery (e.g., discectomies, laminectomies, foraminotomies, or fusion).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic low-back pain are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Altoona Center of Clinical Research
Duncansville, Pennsylvania, 16635, United States
-
Arizona Research Center
Phoenix, Arizona, 85053, United States
-
Drug Studies America
Marietta, Georgia, 30060, United States
-
Drug Trials America
Hartsdale, New York, 10530, United States
-
JBR Clinical Research
Salt Lake City, Utah, 84107, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can naming your feelings predict back pain relief?
- Scientists map the daily rhythms of chronic pain
- Can yoga ease back pain when recovery looks unlikely?
- Can exercise retraining rewire the nervous system in chronic back pain?
- Can gentle back vibration reset the Brain's pain response?
- A vibrating belt might soothe the back pain that plagues desk jobs